Osteoporosis therapies: Evidence from health-care databases and observational population studies

Calcified Tissue International

Volumn 87, Issue 5, 2010, Pages 375-384

  Silverman, Stuart L ^a  

^a NONE

Author keywords

Effectiveness; Observational database study; Osteoporosis; Osteoporosis treatment; Randomized controlled trial

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID;

BONE DENSITY; CLINICAL PRACTICE; CLINICAL TRIAL; DATA BASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FRACTURE REDUCTION; HOSPITAL COST; HUMAN; OBSERVATIONAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION; TREATMENT PLANNING; VERTEBRA FRACTURE;

CLINICAL TRIALS AS TOPIC; DATABASES AS TOPIC; EPIDEMIOLOGIC RESEARCH DESIGN; EVIDENCE-BASED MEDICINE; HUMANS; OSTEOPOROSIS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78650177455     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-010-9400-1     Document Type: Review

References (65)

1. R Burge B Dawson-Hughes DH Solomon JB Wong A King A Tosteson 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 465 475 10.1359/jbmr.061113 17144789 (Pubitemid 46797130)
2. Lindsay R, Borisov NN, Sheer RL, Steinbuch M (2005) Impact of early osteoporosis treatment on subsequent fracture prevention among women with clinical vertebral fracture. Presented at: Annual Meeting of the American Society for Bone and Mineral Research, September 23-27, Nashville, TN, abstract M293
3. TW Downey SH Foltz SJ Boccuzzi MA Omar KH Kahler 2006 Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting South Med J 99 570 575 10.1097/01.smj.0000221637.90495.66 16800411 (Pubitemid 43999919)
4. JC Lo AR Pressman MA Omar B Ettinger 2006 Persistence with weekly alendronate therapy among postmenopausal women Osteoporos Int 17 922 928 1:CAS:528:DC%2BD28XkvVCnurY%3D 10.1007/s00198-006-0085-2 16609824 (Pubitemid 43781507)
5. RH Stables 2002 Observational research in the evidence based environment: eclipsed by the randomised controlled trials? Heart 87 101 102 1:STN:280:DC%2BD38%2FntVGjsw%3D%3D 10.1136/heart.87.2.101 11796537
6. EL Hannan 2008 Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations J Am Coll Cardiol Intv 1 211 217
7. BR Motheral KA Fairman 1997 The use of claims databases for outcomes research: rationale, challenges, and strategies Clin Ther 19 346 366 1:STN:280:DyaK2s3pslWjsQ%3D%3D 10.1016/S0149-2918(97)80122-1 9152572 (Pubitemid 27239651)
8. R Dowd RR Recker RP Heaney 2000 Study subjects and ordinary patients Osteoporos Int 11 533 536 1:STN:280:DC%2BD3cvotFShtw%3D%3D 10.1007/s001980070097 10982170
9. LC Ward JW Fielding JA Dunn KA Kelly 1992 The selection of cases for randomised trials: a registry survey of concurrent trial and non-trial patients. The British Stomach Cancer Group Br J Cancer 66 943 950 1:STN:280: DyaK3s%2FktFSnuw%3D%3D 1419641
10. MJ Cziraky VJ Willey JM McKenney SA Kamat MD Fisher JR Guyton, et al. 2006 Statin safety: an assessment using an administrative claims database Am J Cardiol 97 61C 68C 1:CAS:528:DC%2BD28XkvF2gsrw%3D 10.1016/j.amjcard.2005.12.011 16581331
11. Vray M, Hamelin B, Jaillon P; Round Table 2, Giens XX (2005) The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs. Therapie 60:339-344
12. JZ Ayanian 1999 Using administrative data to assess health care outcomes Eur Heart J 20 1689 1691 1:STN:280:DC%2BD3cvnt1SmtA%3D%3D 10.1053/euhj.1999.1823 10562474
13. ES Siris ST Harris CJ Rosen CE Barr JN Arvesen JA Abbott, et al. 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 1013 1022 10.4065/81.8.1013 16901023
14. JA Cramer DT Gold SL Silverman EM Lewiecki 2007 A systematic review of persistence and compliance with bisphosphonates for osteoporosis Osteoporos Int 18 1023 1031 1:CAS:528:DC%2BD2sXntVOlsrY%3D 10.1007/s00198-006-0322-8 17308956 (Pubitemid 47019996)
15. Van Staa TP, Geusens P, Leufkens HG, Cooper C (2005) Persistence to bisphosphonate treatment in actual clinical practice. Second joint meeting of the European Calcified Tissue Society and the International Bone and Mineral Society, 25-29 June, Geneva, Switzerland, abstract P610-Su
16. CM Couris A Duclos M Rabilloud S Couray-Targe R Ecochard PD Delmas, et al. 2007 A seventy percent overestimation of the burden of hip fractures in women aged 85 and over Bone 41 896 900 10.1016/j.bone.2007.06.020 17715006 (Pubitemid 47593008)
17. SB Jaglal I Weller M Mamdani G Hawker H Kreder L Jaakkimainen, et al. 2005 Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res 20 898 905 10.1359/JBMR.041231 15883628 (Pubitemid 40712812)
18. T Chevalley E Guilley FR Herrmann P Hoffmeyer CH Rapin R Rizzoli 2007 Incidence of hip fracture over a 10-year period (1991-2000): reversal of a secular trend Bone 40 1284 1289 1:STN:280:DC%2BD2s3itFWgsA%3D%3D 10.1016/j.bone.2006.12.063 17292683 (Pubitemid 46550978)
19. F Borgström N Zethraeus O Johnell L Lidgren S Ponzer O Svensson, et al. 2006 Costs and quality of life associated with osteoporosis-related fractures in Sweden Osteoporos Int 17 637 650 10.1007/s00198-005-0015-8 16283064
20. N Black 1996 Why we need observational studies to evaluate the effectiveness of health care BMJ 312 1215 1218 1:STN:280:DyaK283hsVGluw%3D%3D 8634569
21. FS Lobo S Wagner CR Gross JC Schommer 2006 Addressing the issue of channeling bias in observational studies with propensity scores analysis Res Social Adm Pharm 2 143 151 17138506
22. A Hartz S Bentler M Charlton D Lanska Y Butani GM Soomro, et al. 2005 Assessing observational studies of medical treatments Emerg Themes Epidemiol 2 8 10.1186/1742-7622-2-8 16137327 (Pubitemid 41365579)
23. K Benson AJ Hartz 2000 A comparison of observational studies and randomized, controlled trials N Engl J Med 342 1878 1886 1:STN:280: DC%2BD3czgt1Chsg%3D%3D 10.1056/NEJM200006223422506 10861324 (Pubitemid 30419053)
24. J Concato N Shah RI Horwitz 2000 Randomized, controlled trials, observational studies, and the hierarchy of research designs N Engl J Med 342 1887 1892 1:STN:280:DC%2BD3czgt1Chsw%3D%3D 10.1056/NEJM200006223422507 10861325 (Pubitemid 30419054)
25. L Wei S Ebrahim C Bartlett PD Davey FM Sullivan TM McDonald 2005 Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials BMJ 330 821 10.1136/bmj.38398.408032.8F 15790616 (Pubitemid 40529803)
26. CP Gross HM Krumholz G Van Wye EJ Emanuel D Wendler 2006 Does random treatment assignment cause harm to research participants? PLoS Med 3 e188 10.1371/journal.pmed.0030188 16719548 (Pubitemid 43987822)
27. AB King KG Saag RT Burge M Pisu N Goel 2005 Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment Osteoporos Int 16 1545 1557 10.1007/s00198-005-1869-5 15942702 (Pubitemid 41790858)
28. HT Sørensen TL Lash KJ Rothman 2006 Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies Hepatology 44 1075 1082 10.1002/hep.21404 17058242 (Pubitemid 44748358)
29. International Osteoporosis Foundation (2010) International costs and utilities related to osteoporotic fractures study (ICUROS), http://www. iofbonehealth.org/health-professionals/health-economics/icuros.html. Cited 23 March 2010
30. TW Weiss DT Gold SL Silverman CA McHorney 2006 An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study Curr Med Res Opin 22 949 960 10.1185/030079906X104740 16709316 (Pubitemid 43875562)
31. R Keen E Jodar G Iolascon HP Kruse A Varbanov B Mann, et al. 2006 European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency Curr Med Res Opin 22 2375 2381 10.1185/030079906X154079 17257451 (Pubitemid 46055200)
32. DT Gold W Safi H Trinh 2006 Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate Curr Med Res Opin 22 2383 2391 1:CAS:528:DC%2BD2sXhsVOlt7k%3D 10.1185/030079906X154042 17257452 (Pubitemid 46055201)
33. AM Gallagher S Rietbrock M Olson TP van Staa 2008 Fracture outcomes related to persistence and compliance with oral bisphosphonates J Bone Miner Res 23 1569 1575 10.1359/jbmr.080510 18505366
34. V Rabenda R Mertens V Fabri J Vanoverloop F Sumkay C Vannecke, et al. 2008 Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women Osteoporos Int 19 811 818 1:CAS:528:DC%2BD1cXltFyjurs%3D 10.1007/s00198-007-0506-x 17999022
35. DT Gold BC Martin JR Frytak MM Amonkar F Cosman 2007 A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis Curr Med Res Opin 23 585 594 1:CAS:528:DC%2BD2sXkt1Wku7Y%3D 10.1185/030079906X167615 17355739 (Pubitemid 46456906)
36. S Silverman 2006 Adherence to medications for the treatment of osteoporosis Rheum Dis Clin North Am 32 721 731 10.1016/j.rdc.2006.07.003 17288974 (Pubitemid 46613878)
37. DT Gold B McClung 2006 Approaches to patient education: emphasizing the long-term value of compliance and persistence Am J Med 119 4 Suppl 1 S32 S37 10.1016/j.amjmed.2005.12.021 16563940
38. FE Cotte P Fardellone F Mercier AF Gaudin C Roux 2010 Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis Osteoporos Int 21 145 155 1:CAS:528:DC%2BD1MXhsFSqtLbJ 10.1007/s00198-009-0930-1 19459025
39. DT Gold H Trinh W Safi 2009 Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy Curr Med Res Opin 25 1831 1839 1:CAS:528:DC%2BD1MXoslalsrw%3D 10.1185/03007990903035604 19530982
40. HG Bone D Hosking J-P Devogelaer JR Tucci RD Emkey RP Tonino, et al. 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 1189 1199 1:CAS:528:DC%2BD2cXit12rsLc%3D 10.1056/NEJMoa030897 15028823 (Pubitemid 38339363)
41. DD Mellström OH Sörensen S Goemaere C Roux TD Johnson AA Chines 2004 Seven years of treatment with risedronate in women with postmenopausal osteoporosis Calcif Tissue Int 75 462 468 10.1007/s00223-004-0286-7 15455188 (Pubitemid 40174503)
42. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley, et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 1:CAS:528:DC%2BD2sXltVSktLc%3D 10.1056/NEJMoa067312 17476007 (Pubitemid 46698462)
43. SR Heckbert G Li SR Cummings NL Smith BM Psaty 2008 Use of alendronate and risk of incident atrial fibrillation in women Arch Intern Med 168 826 831 1:CAS:528:DC%2BD1cXmtFSrsLk%3D 10.1001/archinte.168.8.826 18443257 (Pubitemid 351649266)
44. HT Sørensen S Christensen F Mehnert L Pedersen RD Chapurlat SR Cummings, et al. 2008 Use of bisphosphonates among women and risk of atrial fibrilation and flutter: population base case-control study BMJ 336 813 816 10.1136/bmj.39507.551644.BE 18334527 (Pubitemid 351548223)
45. TJ Bunch JL Anderson HT May JB Muhlestein BD Horne BG Crandall, et al. 2009 Relation of bisphosphonate therapies and risk of developing atrial fibrillation Am J Cardiol 103 824 828 1:CAS:528:DC%2BD1MXisl2rtrY%3D 10.1016/j.amjcard.2008.11.037 19268739
46. B Abrahamsen P Eiken R Eastell 2009 Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study J Bone Miner Res 24 1095 1102 1:CAS:528:DC%2BD1MXmvFyjtrY%3D 10.1359/jbmr.081247 19113931
47. DK Wysowski 2009 Reports of esophageal cancer with oral bisphosphonate use N Engl J Med 360 89 90 1:CAS:528:DC%2BD1MXitVShug%3D%3D 10.1056/NEJMc0808738 19118315
48. NB Watts K Worley A Solis J Doyle R Sheer 2004 Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database J Manag Care Pharm 10 142 151 15032563
49. DM Black DE Thompson DC Bauer K Ensrud T Musliner MC Hochberg, et al. 2000 Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group J Clin Endocrinol Metab 85 4118 4124 1:CAS:528:DC%2BD3cXotlWnurw%3D 10.1210/jc.85.11.4118 11095442 (Pubitemid 32055362)
50. JT Harrington LG Ste-Marie ML Brandi R Civitelli P Fardellone A Grauer, et al. 2004 Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis Calcif Tissue Int 74 129 135 1:CAS:528:DC%2BD2cXhtFGjt78%3D 10.1007/s00223-003-0042-4 14648009 (Pubitemid 38263854)
51. SM Cadarette JN Katz MA Brookhart T Sturmer MR Stedman DH Solomon 2008 Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture Ann Intern Med 148 637 646 18458276
52. SL Silverman NB Watts PD Delmas JL Lange R Lindsay 2007 Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study Osteoporos Int 18 25 34 1:CAS:528:DC%2BD28Xht1OhtrfI 10.1007/s00198-006-0274-z 17106785 (Pubitemid 44885493)
53. North American Menopause Society 2006 Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society Menopause 13 340 367 10.1097/01.gme.0000222475.93345.b3
54. CJ Rosen MC Hochberg SL Bonnick M McClung P Miller S Broy, et al. 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study J Bone Miner Res 20 141 151 1:CAS:528:DC%2BD2MXptValtA%3D%3D 10.1359/JBMR.040920 15619680
55. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt, et al. 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1535 1541 1:CAS:528:DyaK2sXisFCktQ%3D%3D 10.1016/S0140-6736(96)07088-2 8950879 (Pubitemid 26411651)
56. UA Liberman SR Weiss J Bröll HW Minne H Quan NH Bell, et al. 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group N Engl J Med 333 1437 1443 1:CAS:528:DyaK28XkslehtA%3D%3D 10.1056/NEJM199511303332201 7477143
57. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner, et al. 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077 2082 1:CAS:528:DyaK1MXjsVWruw%3D%3D 10.1001/jama.280.24.2077 9875874 (Pubitemid 29014065)
58. ST Harris NB Watts HK Genant CD McKeever T Hangartner M Keller, et al. 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352 1:CAS:528:DyaK1MXmvFansr0%3D 10.1001/jama.282.14.1344 10527181 (Pubitemid 29483192)
59. J Reginster HW Minne OH Sorensen M Hooper C Roux ML Brandi, et al. 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 83 91 1:CAS:528:DC%2BD3cXhvFGgsr0%3D 10.1007/s001980050010 10663363 (Pubitemid 30099515)
60. JR Curtis AO Westfall H Cheng KG Saag E Delzell 2009 Risedronate and Alendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction Osteoporos Int 20 973 978 1:CAS:528:DC%2BD1MXls12kt74%3D 10.1007/s00198-008-0772-2 18946630
61. ST Harris JY Reginster C Harley WA Blumentals SA Poston CE Barr, et al. 2009 Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the Evaluation of Ibandronate Efficacy (VIBE) database fracture study Bone 44 758 765 1:CAS:528:DC%2BD1MXktFags7c%3D 10.1016/j.bone.2009.01.002 19168160
62. Abelson A, Ringe JD, Gold DT, Lange JL, Thomas T (2009) Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporos Int. doi: 10.1007/s00198-009-1046-3
63. PD Miller SL Silverman DT Gold KA Taylor P Chen RB Wagman 2006 Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study Osteoporos Int 17 85 90 10.1007/s00198-005- 1915-3 15981021 (Pubitemid 41798031)
64. Sebba A, Sierra-Zorita R, Miller P, Chen P, Taylor K, Wong M, et al (2007) The Direct Assessment of Non-vertebral Fracture in the Community Experience (DANCE) study: baseline demographics and reasons for initiating teriparatide therapy. Presented at: Annual Meeting of the American Society for Bone and Mineral Research, September 16-19, Honolulu, HI, abstract W303
65. Taylor K, Gold D, Silverman S, Chen P, Wong M, Krohn K (2007) Persistence with teriparatide therapy among participants in the DANCE trial. Presented at: Annual Meeting of the American Society for Bone and Mineral Research, September 16-19, Honolulu, HI, abstract W384